Acupuncture Tested in Adults With Prediabetes and Obesity
Tests acupuncture against sham acupuncture in adults with prediabetes and obesity.
Plain-language title generated from the registry record
Registry title: Acupuncture for Prediabetes With Combined Obesity
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT06359418, who can take part
Where in China
- Guang 'anmen Hospital, China Academy of Chinese Medical SciencesBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Trial code
- NCT06359418
- Record updated
- 22 August 2025
- Original description
The clinical trial aims to evaluate the efficacy and safety of acupuncture in reducing weight and waist circumference while modulating glucose and lipid metabolism in Prediabetes with Combined Obesity.Read full original descriptionShow less
Acupuncture for Prediabetes With Combined Obesity: a Multicenter Randomized Controlled Trial
The clinical trial aims to evaluate the efficacy and safety of acupuncture in reducing weight and waist circumference while modulating glucose and lipid metabolism in Prediabetes with Combined Obesity.
Inclusion: -; Subjects are eligible to be included in the trial only if all of the following criteria apply:; Simultaneously meeting the diagnostic criteria for both general obesity, abdominal obesity, and prediabetes; Aged 18-64 years old; Informed consent obtained before any trial-related activities.
Exclusion: Current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic corticosteroids (except for a short course of treatment, i.e. 7-10 days), antidepressants, antipsychotic, mood stabilizers, antiepileptic and hormone contraceptive; Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device; Current participation (or within the last month) in an organized weight reduction program or currently using or used medication for obesity or hyperglycemia within 3 months before screening: liraglutide, exenatide, pramlintide, orlistat, topiramate, phenteremine, or metformin (either by prescription or as part of a clinical trial); A self-reported change in body weight >5 kg within 3 months before screening irrespective of medical records; Serious medical conditions (including but not limited to ongoing renal or hepatic insufficiency, congestive heart failure, myocardial infarction, stroke, hematopoietic system diseases, progressive malignant tumor or other serious consumptive diseases); history of angina pectoris, transient ischemic attack, claudication, or acute limb ischemia within the past 6 months prior to screening; Serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder, (e.g. borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt or current active suicidal ideation, recent hospitalization due to psychiatric illness; Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established Polycystic Ovary Syndrome); Diagnosis of type 1 or type 2 diabetes per the judgment of the investigator; History of pancreatitis or pancreatectomy; Skin infection, blood coagulation disorders and other conditions that are not suitable for acupuncture; Metal allergies or severe fear of needles; Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol; impaired glucose regulation due to hyperthyroidism, endocrine tumors and extensive liver damage; -; Subjects are excluded from the trial if any of the following criteria apply:; Pregnant or breast-feeding women or planning to become pregnant during the study period.